MX2015015058A - Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona. - Google Patents

Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.

Info

Publication number
MX2015015058A
MX2015015058A MX2015015058A MX2015015058A MX2015015058A MX 2015015058 A MX2015015058 A MX 2015015058A MX 2015015058 A MX2015015058 A MX 2015015058A MX 2015015058 A MX2015015058 A MX 2015015058A MX 2015015058 A MX2015015058 A MX 2015015058A
Authority
MX
Mexico
Prior art keywords
dihydro
compounds
isoindol
isoquinoline
new
Prior art date
Application number
MX2015015058A
Other languages
English (en)
Other versions
MX368759B (es
Inventor
Rainer E Martin
Yongfu Liu
Lisha Wang
Johannes Aebi
Kurt Amrein
Benoit Hornsperger
Bernd Kuhn
Hans P Maerki
Alexander V Mayweg
Xuefei Tan
Mingwei Zhou
Wenming Chen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015015058A publication Critical patent/MX2015015058A/es
Publication of MX368759B publication Critical patent/MX368759B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona nuevos compuestos que tienen la fórmula general (I) en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 R11, R12, R13, R14, R15, A, m, n y p son tal como se describe en el presente documento, composiciones que incluyen los compuestos y métodos de uso de los compuestos.
MX2015015058A 2013-05-27 2014-05-26 Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona. MX368759B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013076285 2013-05-27
PCT/EP2014/060794 WO2014191340A1 (en) 2013-05-27 2014-05-26 New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds

Publications (2)

Publication Number Publication Date
MX2015015058A true MX2015015058A (es) 2016-02-11
MX368759B MX368759B (es) 2019-10-15

Family

ID=50819739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015058A MX368759B (es) 2013-05-27 2014-05-26 Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.

Country Status (20)

Country Link
US (1) US9695152B2 (es)
EP (1) EP3004076B1 (es)
JP (2) JP6416230B2 (es)
AR (1) AR096425A1 (es)
BR (1) BR112015029691B1 (es)
CA (1) CA2902848C (es)
DK (1) DK3004076T3 (es)
ES (1) ES2763424T3 (es)
HK (1) HK1213556A1 (es)
HR (1) HRP20192242T1 (es)
HU (1) HUE046739T2 (es)
LT (1) LT3004076T (es)
MX (1) MX368759B (es)
PL (1) PL3004076T3 (es)
PT (1) PT3004076T (es)
RS (1) RS59663B1 (es)
RU (1) RU2693698C2 (es)
SI (1) SI3004076T1 (es)
TW (1) TWI704143B (es)
WO (1) WO2014191340A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416229B2 (ja) * 2013-05-27 2018-10-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新しい３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物
ES2850198T3 (es) * 2014-10-08 2021-08-26 Hoffmann La Roche Derivados de espirodiamina como inhibidores de la aldosterona sintasa
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
EP2627648A1 (en) * 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
KR101785143B1 (ko) * 2011-09-15 2017-10-12 에프. 호프만-라 로슈 아게 다이하이드로퀴놀린-2-온 유도체
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives

Also Published As

Publication number Publication date
JP2019014738A (ja) 2019-01-31
AR096425A1 (es) 2015-12-30
US9695152B2 (en) 2017-07-04
CA2902848A1 (en) 2014-12-04
JP6416230B2 (ja) 2018-10-31
HUE046739T2 (hu) 2020-03-30
EP3004076B1 (en) 2019-10-23
ES2763424T3 (es) 2020-05-28
JP2016520106A (ja) 2016-07-11
DK3004076T3 (da) 2020-01-02
LT3004076T (lt) 2020-01-10
US20160075688A1 (en) 2016-03-17
RU2693698C2 (ru) 2019-07-04
HRP20192242T1 (hr) 2020-03-06
EP3004076A1 (en) 2016-04-13
WO2014191340A1 (en) 2014-12-04
SI3004076T1 (sl) 2020-02-28
BR112015029691B1 (pt) 2023-03-28
PL3004076T3 (pl) 2020-04-30
TW201534596A (zh) 2015-09-16
TWI704143B (zh) 2020-09-11
HK1213556A1 (zh) 2016-07-08
CA2902848C (en) 2021-09-21
BR112015029691A2 (pt) 2017-07-25
MX368759B (es) 2019-10-15
RU2015149956A3 (es) 2018-03-19
RU2015149956A (ru) 2017-07-04
PT3004076T (pt) 2019-12-18
RS59663B1 (sr) 2020-01-31

Similar Documents

Publication Publication Date Title
PH12017500658B1 (en) Spirodiamine derivatives as aldosterone synthase inhibitors
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
MY169043A (en) New dihydroquinoline-2-one derivatives
PH12017501825B1 (en) Bicyclic quinazolinone derivatives
IN2015DN00960A (es)
MY186165A (en) New bicyclic dihydroquinoline-2-one derivatives
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MX351581B (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX343225B (es) Nuevos derivados de aril-benzocicloalquil-amida.
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
MY169267A (en) New aryl-quinoline derivatives
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2012008141A (es) Compuestos y metodos.
MX370389B (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX366678B (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2013005753A (es) Nuevos derivados de biaril amida.
GEP20186893B (en) Pyrazines modulators of gpr6
MX368759B (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX2015011005A (es) Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.
MX2016002762A (es) Derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa.
MX2015009377A (es) Compuestos radiomarcados.
TW201613947A (en) Dinitrosyl iron complexes, uses thereof, and water splitting device using the same

Legal Events

Date Code Title Description
FG Grant or registration